Table 2.
Clinical and biochemical parameters for the control and VTE groups.
| Control (n = 57) | VTE (n = 54) | p Value | |
|---|---|---|---|
| Age at baseline (y) | 64 (48–75) | 61.5 (46.8–78) | 0.873 |
| Gender (% males) | 40.4 | 40.7 | 0.967 |
| BMI (Kg/m2) | 26 (24.2–29) | 27.6 (24.2–29.7) | 0.335 |
| Smoking (n, %) | 10 (17.5) | 10 (18.5) | 0.894 |
| Alcohol consumption (n, %) | 28 (49.1) | 26 (48.1) | 0.918 |
| Hypertension (n, %) | 23 (40.4) | 26 (48.1) | 0.408 |
| Dyslipidemia (n, %) | 19 (33.3) | 17 (31.5) | 0.835 |
| Statins (n, %) | 14 (24.6) | 14 (25.9) | 0.869 |
| Diabetes mellitus (n, %) | 7 (12.3) | 2 (3.7) | 0.098 |
| Autoimmune disease (n, %) | 7 (12.3) | 5 (9.3) | 0.608 |
| Arterial thrombosis background (n, %) |
- | 2 (3.7) | 0.239 |
| Anti-platelet drugs (n, %) | 2 (3.5) | 8 (14.8) | 0.049 |
| PFA_ADP (s) | 82 (72–96.8) | 59 (54.8–63) | <0.0001 |
| PFA_EPI (s) | 116.5 (97.8–137.8) | 83 (77–88) | <0.0001 |
| Platelet count (×109/L) | 234 (204–270.5) | 234 (203–268.8) | 0.750 |
| eGFR (mL/min/1.73 m2) | 85.4 (66.7–90) | 70.8 (60–90) | 0.012 |
| ALT (IU/L) | 18 (15–24) | 20 (16–35.5) | 0.060 |
| AST (IU/L) | 19 (16–21) | 19 (16–21) | 0.266 |
PFA_ADP: platelet function analysis adenosine 5′-diphosphate; PFA_EPI: platelet function analysis epinephrine; BMI: body mass index; eGFR: estimated glomerular filtration rate; ALT: alanine amino transferase; AST: aspartate amino transferase. Results are expressed as median (P25–P75). A Mann–Whitney U test was performed to compare differences between the control and VTE groups.